Mydecine announces an LOI to co-develop its own digital therapeutics platform, in partnership with Maya Health.
Exploring the companies and themes that make up this emerging and exciting new sector
The Year In Review For Psychedelic Drug Stocks: 2021
2021 was two different "years" for the psychedelic drug industry. Impressive progress in drug R&D and clinics; stocks pushed down to absurdly lean multiples.
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights
Awakn Life Sciences reports its Q3 for fiscal 2021. Highlights include key IP and clinic acquisitions, and the company's first revenues.
MINDCURE Nears Finish Line With iSTRYM Commercialization
MINDCURE moves an important step closer to the full commercial deployment of its iSTRYM digital therapeutics platform, and also makes a key addition to its management team.
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
Cybin Inc receives its Notice of Allowance from the USPTO with respect to its patent for CYB004.
The Military Mental Health Crisis, A National Tragedy: Part I
The ongoing and worsening mental health crisis in the U.S. military is a national tragedy and a national disgrace. Part I reveals the ugly Big Picture.
MINDCURE (CSE: MCUR) (OTCQX: MCURF) Appoints Dr. Doron Sagman as Chief Medical Officer
Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) announces the appointment of Doron Sagman, MD, FRCPC, as the Company’s new Chief Medical Officer (“CMO”)
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia
atai partner, Recognify Life Sciences, reports positive Phase 2a results in treating Cognitive Impairment Associated with Schizophrenia.
MindMed Appoints Robert Barrow as Chief Executive Officer and Director
MindMed announces that interim CEO Robert Barrow has now been named the permanent CEO, and added as a Director.
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
Compass Pathways announces parallel treatment results with COMP360 for patients continuing to take SSRI-based antidepressants.
Numinus Wellness Inc. Reports Q4 and Year End 2021 Results
Numinus reports strong revenue growth, a gross profit on Q4 clinic operations, and cash position of CAD$59.2 million.
Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
Mydecine raises CAD$.5.5 million via convertible debenture and provided a corporate update, including news on its future Phase 2/3 smoking cessation trial.